Jesagawa's first anti-epileptic drug is coming! 5 billion market 8 varieties will be the first review

Jichuan Pharmaceutical's first anti-epileptic drug cameFigure 1: 2018 China's public medical institutions terminal chemical drug Jichuan Pharmaceutical Group's sub-patternsource: Minet China's public medical institutions terminal competition pattern
According to Jichuan Pharmaceutical's annual report data show that the company's pharmaceutical product line mainly around pediatrics, breathing, digestion and other fieldsmeters of internal data show that in 2018 in China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal chemical drug market, Jichuan Pharmaceuticals, the main sub-class for the treatment of gastric acid secretion-related diseases, accounted for up to 78.08 percent, in addition, in the nervous system drugs have anaesthetic, painkillers, psychosis drugs, no anti-epileptic drugs, if the success of the left-ilacin injection, the first drug to be approvedTable 1: 2018 Jichuan Pharmaceuticals in China's public medical institutions terminal chemical drug market TOP10 variety situationsource: Minet China public medical institutions terminal competition pattern
in China's public medical institutions terminal chemical drug market, the largest contribution to the performance of Jichuan Pharmaceuticals is the treatment of gastric acid secretion-related diseases of the drug Rebellazine, accounting for more than 76%, in addition, in addition, Proteins succinic acid, lidocaine, rice inositol B12, diacetaminodeace and diamine also contributed more than 1% of the performanceanti-epileptic drug market will break 5 billion yuan
Figure 2: 2018 China's public medical institutions terminal chemical drug anti-epileptic drug annual sales (unit: million yuan)source: Minet China's public medical institutions terminal competition patternepilepsy is second only to the common chronic neurological diseases in stroke, in any age, region and race of the population have the incidence of children and the elderly as two peaksEpilepsy treatment is mainly divided into drugs, surgery and other treatment (e.gdiet, biofeedback, etc.), 70% of patients through drug treatment can be effectively controlled, and then slowly reduce the drug, after a few years, the final drug suspensionwith the gradual increase of patient groups, anti-epileptic drug market size is also rising rapidly, in 2013 in China's public medical institutions end chemical drug anti-epileptic drug market size of 2 billion yuan, in 2018 soared to 4.9 billion yuan, in 2019 to exceed 5 billion yuan is also a high probability event, 2014-2017 sales growth rate of more than 10%, is one of the best performing sub-category of neuropharmaceuticalsTable 2: China's public medical institutions terminal chemical drug anti-epileptic drug generic name listsource: Minet China's public medical institutions terminal competition pattern 19 generic drug sales constitute the total size of China's public medical institutions terminal chemical drug anti-epileptic drug market, these 19 common names, currently only left eracetam has related products over-reviewed, and left elaci tatan has become the first batch of shopping varieties Table 3: The evaluation of the left ethyl lasitan related products note: the winning price according to the "4 plus 7 city drug centralized procurement to select the results of the public ity table", "alliance region drug centralized procurement results list" data in the world's best-selling anti-epileptic drugs, as a broad-spectrum anti-epileptic drug left eclampsia treatment, and not with other anti-epileptic drugs to interact with the first good Whether from the enterprise in the choice of consistency evaluation, or from the national level to let it into the first batch of quantity procurement catalog selection, we can see that the clinical value of left eracetam and market potential is huge 9 varieties of the road to evaluation of the road table 4: currently under review of anti-epileptic drug consistency evaluation and new classification of generic drug listing application source: Minet MED China Drug Review Database 2.0 As of December 31, 2019, 19 anti-epileptic drug species, 7 The consistency evaluation of large varieties (involving 7 products) is being reviewed and approved, of which the consistency evaluation of the Gabba spray capsule sits between Enhua and Hengrui, the product in China's public medical institutions terminal sales of more than 200 million yuan, the current market share of Enhua and Hengrui is 50.11%, 36.55% in the new classiasgeneric sizzle, 6 major varieties (involving 13 products) of the 3 categories, 4 types of imitation listing applications are being reviewed and approved, if successfully approved as a consistent evaluation, including the domestic neurochemical drug leader Yangzijiang Pharmaceutical Group, Qilu Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, Jiangsu Enhua Pharmaceuticals and other active participation Popular varieties of left ethyl lasitan continue to lead, 7 major products have the acceptance number of enterprises in the review, left ethyl lasitan sodium chloride injection, left ethyl lacitan oral solution and left ethyl lacsitan injection with concentrated solution is expected to usher in the first review conclusion meter net data show that at present, China's public medical institutions terminal chemical drug anti-epileptic drug market TOP3 enterprises are foreign-funded pharmaceutical enterprises, Sanofi, Youshibi pharmaceutical total market share of nearly 55%, domestic replacement of the original research space is very large, with domestic pharmaceutical companies continue to strive for strength, China's anti-epileptic drug market will continue to bloom source: Internet database review data statistics as of 31 December 2019